PAI-1

抑制剂选择性比较

PAI-1产品

所有产品(6) PAI-1抑制剂(6)

目录号	产品描述	文献引用	实验数据
S9194	Toddalolactone Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.
S7922	Tiplaxtinin (PAI-039) Tiplaxtinin(PAI-039)是口服有效的选择性纤溶酶原激活物抑制剂-1(PAI-1)抑制剂，IC50为2.7 μM。	Cell Rep, 2020, 33(2):108253 Cancers (Basel), 2019, 11(11)E1651 Mol Cancer Res, 2019, 17(5):1142-1154	(H) IF indicating Pcna+ and GFP+ cells after TP treatment (regime indicated at top). (I) Scatter plot of the relative number of Pcna+ cells among all wound and wound-adjacent GFP+ cells. Mean±s.d.; t-test, P<0.05. (J) FISH combined with IHC showing that TP treatment increases cdh5 mRNA levels in GFP+ wound endocardium. (K) Scatter plot of relative red fluorescence intensity, comparing values of remote and wound endocardium (see Fig. 2F). Mean±s.d.; t-test, *P<0.01.
S3242^New	Loureirin B Loureirin B (LB, LrB)，是从Dracaena cochinchinensis中提取的类黄酮，是 PAI-1 的抑制剂，其IC50值为26.10 μM。Loureirin B 可下调TGF-β1刺激的成纤维细胞中的 p-ERK 和 p-JNK。Loureirin B 主要通过增加Pdx-1、MafA、细胞内ATP水平来促进胰岛素分泌，抑制 K_ATP 电流，Ca²⁺ 进入细胞内。
S3785	Notoginsenoside R1 Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.	J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S6776	TM5275 Sodium TM 5275 sodium 是一种口服的、生物活性的 plasminogen activator inhibitor-1 (PAI-1) 抑制剂，其IC50值为6.95 μM。
S6778	TM5441 TM5441是一种口服生物活性的 plasminogen activator inhibitor-1 (PAI-1) 抑制剂，其IC50值介于9.7 μM 和60.3 μM 之间。TM5441可诱导几种人类癌细胞系的内源性细胞凋亡。

目录号	产品描述	文献引用	实验数据
S9194	Toddalolactone Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.
S7922	Tiplaxtinin (PAI-039) Tiplaxtinin(PAI-039)是口服有效的选择性纤溶酶原激活物抑制剂-1(PAI-1)抑制剂，IC50为2.7 μM。	Cell Rep,2020, 33(2):108253 Cancers (Basel),2019, 11(11)E1651 Mol Cancer Res,2019, 17(5):1142-1154	(H) IF indicating Pcna+ and GFP+ cells after TP treatment (regime indicated at top). (I) Scatter plot of the relative number of Pcna+ cells among all wound and wound-adjacent GFP+ cells. Mean±s.d.; t-test, P<0.05. (J) FISH combined with IHC showing that TP treatment increases cdh5 mRNA levels in GFP+ wound endocardium. (K) Scatter plot of relative red fluorescence intensity, comparing values of remote and wound endocardium (see Fig. 2F). Mean±s.d.; t-test, *P<0.01.
S3242^New	Loureirin B Loureirin B (LB, LrB)，是从Dracaena cochinchinensis中提取的类黄酮，是 PAI-1 的抑制剂，其IC50值为26.10 μM。Loureirin B 可下调TGF-β1刺激的成纤维细胞中的 p-ERK 和 p-JNK。Loureirin B 主要通过增加Pdx-1、MafA、细胞内ATP水平来促进胰岛素分泌，抑制 K_ATP 电流，Ca²⁺ 进入细胞内。
S3785	Notoginsenoside R1 Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.	J Ethnopharmacol,2021, S0378-8741(21)00169-0
S6776	TM5275 Sodium TM 5275 sodium 是一种口服的、生物活性的 plasminogen activator inhibitor-1 (PAI-1) 抑制剂，其IC50值为6.95 μM。
S6778	TM5441 TM5441是一种口服生物活性的 plasminogen activator inhibitor-1 (PAI-1) 抑制剂，其IC50值介于9.7 μM 和60.3 μM 之间。TM5441可诱导几种人类癌细胞系的内源性细胞凋亡。